vytorin

WASHINGTON (AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug....

ORLANDO, Fla. (AP) -- A new study raises fresh concerns about Zetia and its cousin, Vytorin - drugs that are still taken by millions of Americans to lower cholesterol, despite questions raised last year about how well they work....

MUNICH (MedPage Today) -- Results of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial presented here left the potent lipid-lowering combination Vytorin still floundering in controversy, but participants in today's roundtable from the European Society of Cardiology sought to soothe troubled waters.

MUNICH, Germany (AP) -- New research into a possible link between a cholesterol-reducing drug and cancer concluded there was no proof to establish a connection, but other doctors warned that it should be used more carefully....

WASHINGTON -- Members of a House committee with a keen interest in the safety of ezetimibe/simvastatin (Vytorin) have asked the FDA to produce the analysis that attempted to clarify a disturbingly high connection between the drug and cancer.

Controversy over the ENHANCE trial continued despite lengthy presentations at the American College of Cardiology meeting earlier this month.

In this exclusive video report MedPage Today talks in-depth with two researchers about ezetimibe, LDL, and clinical implications of the trial.Part 2: Trial DesignPart 3: Clinical Implications

Controversy over the ENHANCE trial continued despite lengthy presentations at the American College of Cardiology meeting earlier this month.

In this exclusive video report MedPage Today talks in-depth with two researchers about ezetimibe, LDL, and clinical implications of the trial.Part 1: Mechanisms of Action DesignPart 3: Clinical Implications

Controversy over the ENHANCE trial continued despite lengthy presentations at the American College of Cardiology meeting earlier this month.

In this exclusive video report MedPage Today talks in-depth with two researchers about ezetimibe, LDL, and clinical implications of the trial.Part 1: Mechanisms of ActionPart 2: Trial Design

WASHINGTON (AP) -- House Democrats are questioning whether Merck and Schering-Plough made up information about a meeting of medical experts to discuss Vytorin, after lawmakers began investigating a failed study of the drug....

CHICAGO (AP) -- Full results of a failed trial on Vytorin, a medicine taken by millions of Americans to lower cholesterol, left doctors stunned that the drug did not improve heart disease even though it worked as intended to lower three key risk factors....